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Abstract: A major function of platelets is keeping the vascular system intact. Platelet activation at sites of 
vascular injury leads to the formation of a hemostatic plug. Activation of platelets is therefore crucial for normal 
hemostasis; however, uncontrolled platelet activation may also lead to the formation of occlusive thrombi that can 
cause ischemic events. Although they are essential for proper hemostasis, platelet function extends to physiologic 
processes such as tissue repair, wound remodeling and antimicrobial host defense, or pathologic conditions such 
as thrombosis, atherosclerosis, chronic inflammatory diseases and cancer. Platelets can be activated by soluble 
molecules including thrombin, thromboxane A2 (TXA2), adenosine diphosphate (ADP), serotonin or by adhesive 
extracellular matrix (ECM) proteins such as von Willebrand factor (vWF) and collagen. Here we describe recent 
advances in the activation of platelets by non-canonical platelet agonists such as galectins. By acting either in soluble 
or immobilized form, these glycan-binding proteins trigger all platelet activation responses through modulation 
of discrete signaling pathways. We also offer new hypotheses and some speculations about the role of platelet-
galectin interactions not only in hemostasis and thrombosis but also in inflammation and related diseases such as 
atherosclerosis and cancer.
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Introduction
Platelet activation and subsequent accumulation at sites of 
vascular injury are the first steps in hemostasis. Excessive 
platelet activation after atherosclerotic plaque rupture or 
endothelial cell erosion may also lead to the formation 
of occlusive thrombi, which are responsible for acute 
ischemic events. Platelets play important roles in several 
physiopathological processes beyond hemostasis and 
thrombosis, including promotion of innate immune and 
inflammatory responses, wound healing, atherosclerosis, 
sepsis, vascular restenosis, acute lung injury and tumor 
growth (1-3). When platelets perceive activating signals 
through their cell surface receptors, they undergo dramatic 
structural and chemical changes, involving a complex 
interplay of cell adhesion and signaling molecules (4).
Galectins are a family of animal lectins that bind beta-
galactosides. Outside the cell, galectins bind to cell-surface 
and extracellular matrix (ECM) glycans and thereby affect 
a variety of cellular processes. However, galectins are also 
detectable in the cytosol and nucleus, and may influence 
cellular functions such as intracellular signaling pathways 
through protein-protein interactions with other cytoplasmic 
and nuclear proteins (5). Although experimental and 
clinical studies have extensively implicated galectins in the 
regulation of immune cell homeostasis and host-pathogens 
interactions, there is increasing evidence that galectins play 
important roles in diverse physiological and pathological 
processes, including immune and inflammatory responses, 
wound repair, tumor development and progression, neural 
degeneration and cardiovascular diseases, in particular 
development of atherosclerosis (6). We have recently 
described that three structurally divergent galectins 
(galectin-1, -3 and -8) either in a soluble or immobilized 
form, are capable of triggering a broad range of platelet 
responses including adhesion and spreading, aggregation, 
release of granule content and P-selectin expression through 
the interaction with the carbohydrate backbone of the major 
platelet receptors involved in hemostasis, e.g., GPIb/IX/V 
complex and integrin αIIbβ3 (7-11).
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In this review we summarize recent knowledge on the 
role of galectins in platelet physiology and the critical 
potential implications of these emerging findings in 
thrombosis, inflammation, atherosclerosis and cancer.
Platelets
Platelets are small (2-4 mm) anucleated spherical cells 
released from bone marrow megakaryocytes during 
thrombopoiesis. They have a lifespan of 7 days in 
peripheral bloodstream circulation and exist for much of 
this time as quiescent sentinels of tissue injury. At sites of 
vascular injury, platelets come into contact with exposed 
subendothelial proteins and form a thrombus for preventing 
bleeding. However, platelet aggregation can also occlude 
atherosclerotic arteries causing cardiac and cerebrovascular 
diseases.
Upon vessel damage, platelets adhere to and become 
activated by the subendothelial collagen-von Willebrand 
factor (vWF) complex and thrombin. Platelet adhesion 
triggers a signaling cascade mediated by tyrosine kinases 
and G-protein coupled receptors, which guide full 
activation of the platelet and concomitant granule release, 
in turn resulting in recruitment and activation of additional 
platelets and the presentation of a procoagulant surface 
promoting formation of a fibrin-rich hemostatic plug at 
the injured site (12). Platelets contain three main type 
of granules: dense bodies contain molecules involved in 
platelet activation and aggregation such as nucleotides, 
cations, phosphates and bioactive amines such as serotonin. 
Lysosomal granules store enzymes such as proteases, 
phosphatases and glycosidases, which are responsible for 
matrix and protein degradation. With 40-80 per platelet, 
α-granules are the most abundant secretory vesicles and 
they contain over 300 soluble and membrane-bound 
molecules including microbicidal peptides, growth factors, 
soluble adhesion molecules and coagulation proteins. 
Additionally, proinflammatory molecules, such as cytokines, 
chemokines and interleukins, are stored in α-granules (4,13). 
As a consequence of platelet adhesion to subendothelium, 
platelets change shape from smooth disks to spiculated 
spheres with filopodia and pseudopodia. Thus, the cargo 
of the granules is released in the surrounding bloodstream 
and recruits and activates further platelets. In addition, 
membrane-bound molecules, for example, P-selectin, 
become translocated to the platelet surface, promoting 
platelet aggregation and interaction with immune and 
endothelial cells. The chemokines and interleukins stored 
in α-granules link platelets to antimicrobial host defense 
and inflammation. Platelets exert antimicrobial effector 
mechanisms, but also initiate an intense crosstalk with 
other arms of the innate and adaptive immunity, including 
neutrophils, monocytes/macrophages, dendritic cells, B 
cells and T cells (13). Furthermore, platelets generate 
microparticles (MPs) with P-selectin, glycoproteins (GPs) 
and CD154 on their surface (3). Platelet activation, in 
addition, also triggers endothelial cells to synthesize and 
secrete molecules which tightly control and limit thrombus 
formation.
Galectins
Galectins are structurally related carbohydrate-binding 
proteins, which are defined by their affinity for poly-N-
acetyllactosamine-enriched glycoconjugates and sequence 
similarities in the carbohydrate recognition domain (CRD). 
These lectins are found in almost all organisms and to 
date 15 galectins have been found in mammals; although 
only 12 galectin genes are found in humans. According to 
their structure, galectins are classified into three groups: (I) 
‘proto-type’ galectins, containing a single CRD including 
galectin-1, -2, -7, -10, -13 and -14; (II) chimeric galectins 
which contain a single CRD and a large amino-terminal non-
lectin domain being galectin-3 its only representative; 
and (III) tandem-repeat type galectins that have two 
CRD linked by a peptide sequence of variable length and 
this subgroup includes galectin-4, -8, -9 and -12 (14). 
Although the CRD sequence is highly conserved among 
galectins, each member of this family recognizes subtly 
different glycan structures and show individual affinities 
for them (15). While galectins that contain one CRD can 
exist as dimers, galectin-3 can form pentamers and most 
galectins can form ordered arrays named lattices when they 
bind to multivalent glycoconjugates (6). Regarding their 
subcellular localization, galectins exhibit a unique pattern as 
they can be found in the nucleus, cytoplasm, outer plasma 
membrane and extracellular matrices shuttling between 
different compartments and displaying a combination of 
intra- and extracellular activities (15,16).
Galectins are pleiotropic regulators of cell physiology 
that participate in many essential processes such as cell 
adhesion, proliferation, differentiation and apoptosis 
(6,15,17,18). They also play unique roles in intracellular 
signaling pathways and cell cycle control (15,19). Moreover, 
galectins participate in wound healing and development as 
well (16).
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Galectins are expressed in a wide variety of tissues. While 
some members, like galectin-1, -3, -8 and -9 show a wide 
tissue distribution, others such as galectin-12 or galectin-7 
show a more restricted localization. Galectin-1, -3, -8 and -9 
are found on cells of the hematopoietic lineage as well as in 
endothelial cells (6,11,14,20). Galectin-2, -4, -7 and -9 are 
expressed in different epithelia and galectin-12 is almost 
exclusively found in adipose tissue (6). Galectin expression is 
also modulated throughout cell activation, inflammation and 
in pathologic processes such as atherosclerosis and cancer.
Galectins induce platelet adhesion and 
aggregation
Platelet adhesion to the ECM at sites of vascular injury 
represents a key step for limiting bleeding. Under low shear 
rate, such as that found in veins and larger arteries, platelet 
adhesion to the vessel wall primarily involves binding to 
fibrilar collagen, fibronectin and laminin. However at 
conditions of elevated shear stress, the initial tethering and 
firm adhesion of platelets to the exposed subendothelium 
is mediated by the interaction of the platelet GP Ib/IX/V 
complex and the subendothelial bound vWF (12). However, 
as vWF-deficient mice have delayed but not absent 
arterial thrombus formation it was suggested that under 
these conditions GPIbα might bind other ligands that can 
mediate platelet adhesion. Interestingly, in vitro studies 
have shown that galectin-8 (9) and -1 (unpublished data) 
promote platelet adhesion and spreading and GPIbα was 
identified as a functional Galectin-8 counter-receptor (9). 
Thus, it could be conceivable that galectins may act directly 
as a substrate or may either behave as matricellular proteins 
that bind to platelet GPIb/IX/V complex thus contributing 
to the platelet adhesion to the ECM.
The capacity of platelets to form a thrombus depends 
on their ability to aggregate. After platelet adhesion 
to the injured endothelium, soluble agonists such as 
adenosine diphosphate (ADP), serotonin, thrombin 
and thromboxane A2 (TXA2), produced/released at the 
site of injury act in autocrine and paracrine manner to 
amplify platelet activation and to recruit circulating 
platelets to the developing thrombus. At a molecular level, 
platelet aggregation is mediated by a specific receptor 
on the platelet surface: the αIIbβ3 integrin (21). Like most 
traditional platelet agonists, both soluble galectin-1 and 
-8 promote the transition of this integrin from a low-
affinity state (resting state) to a high-affinity state (active 
state), which results in the unmasking of neoepitopes in 
the αIIbβ3 complex, and allows fibrinogen binding which 
acts as a bridging molecule between platelets to form 
aggregates (7,9). This conformational change of αIIbβ3 
integrin triggered by galectins is accompanied by a raise in 
intracellular calcium levels as well as morphological changes 
of platelets involving the rearrangement of the cytoskeleton 
including extension of filopodia and lamellipodia (spreading) 
and F-actin polymerization (7).
Both galectin-1 and -8 induce aggregation of platelets 
suspended either in plasma or buffer which indicates a 
relevant role of these lectins in physiological media (7,9). 
Although cell agglutination was one of the first biological 
activities described for these lectins, this effect on platelets 
was only observed at high galectin-1 and -8 concentrations. 
Platelet aggregation at lower concentrations is absent in 
fixed platelets, in the presence of calcium chelating agents, 
or eptifibatide (an αIIbβ3 antagonist), implying that platelet 
responses mediated by galectins could be related either to 
cell activation or to a clustering effect of platelet surface 
receptors depending on their concentration (7,9). Although 
both galectins were capable of promoting aggregation, 
galectin-8 was found to be 10 times more potent than 
galectin-1 in this stimulatory effect. Although the dimeric 
structure of galectin-8 would anticipate a more robust effect 
of this galectin compared to galectin-1, the observation that 
only the N-terminal domain was also able to trigger platelet 
activation indicates that lectin bivalency is not essential to 
promote activating effects on platelets (9). The differences 
in the concentration required to achieve a similar effect, 
could therefore reflect different downstream molecular 
signals triggered by each galectin.
The initial formation of platelet thrombus is rapidly 
reinforced by the generation and release of platelet TXA2 and 
ADP (the main metabolite of arachidonic acid by the cyclo-
oxigenase pathway, and a component of platelet dense granules 
respectively) which acting in a paracrine and autocrine manner 
promote further platelet activation (4). Both molecules are 
generated on platelet stimulation by galectin-1 and -8. 
Moreover, although the aggregation response triggered 
by low galectin-8 concentrations was inhibited in the 
presence of aspirin (cyclo-oxigenase inhibitor) and/or an 
ADP-scavenger, a full response was obtained at higher 
concentrations indicating that galectin-8 is a strong agonist 
that activate platelets independently from TXA2 formation 
or ADP release (9).
What is the relevance of platelet activation mediated by 
galectins in vivo? Given the described effects of galectin-1 
and -8 in platelet physiology, exposure of these endogenous 
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lectins in the subendothelium or in activated endothelial 
cells (20) is expected to trigger platelet adhesion, spreading 
and thrombus formation. Moreover, in the vascular 
system, platelets are another source of galectin-8 (9) that 
would be accessible upon platelet activation to eventually 
promote further thrombus growth. In support of these 
hypotheses, evaluation of hemostasis in vivo by tail bleeding 
revealed increased bleeding time in galectin-1 knockout 
animals, which was not associated to a lower platelet 
count. In addition, galectin-1-deficient platelets exhibited 
impaired kinetics of clot retraction and platelet spreading 
on fibrinogen in the presence of normal integrin αIIbβ3 
expression. Galectin-1-deficient platelets showed normal 
α granule secretion and normal platelet aggregation. 
Therefore, galectin-1 appears to regulate integrin αIIbβ3 
“outside-in” signaling events in platelets and is necessary for 
normal primary hemostasis in vivo (8). Whether this effect is 
specific for galectin-1 or is a general feature to all galectins, 
is an interesting question that remains to be investigated.
Thrombosis and disseminated intravascular coagulation 
are common complicat ions in cancer pat ients .  A 
hypercoagulable or prothrombotic state of malignancy 
occurs due to the ability of tumor cells to activate platelets 
and the coagulation system. Prothrombotic factors in cancer 
include the ability of tumor cells to produce and secrete 
procoagulant/fibrinolitic substances and inflammatory 
cytokines and the physical interaction between tumor cell 
and platelets (22). However, the mechanisms allowing the 
occurrence of prothrombotic states in cancer patients are 
not completely understood. The observed increased levels 
of galectin-1 and -8 in tumoral endothelial cells as well 
as in other malignant cells could represent a pathogenic 
mechanism involved in thrombosis and disseminated 
intravascular coagulation complications, commonly present 
in cancer patients. Given the pivotal role of galectin-1 
and -8 in tumor progression, it could be conceivable that 
galectin-induced platelet activation might contribute to the 
pathogenesis of thrombosis in cancer patients.
Platelet-galectin interactions, potential 
regulators of the inflammatory, atherosclerosis 
and metastatic processes
The contribution of platelets to the inflammatory response 
is an outcome of the interaction of platelets with leukocytes 
and endothelial cells. Stimulated “sticky” platelets express 
on their cell surface, P-selectin and CD40L α-granule-
stored proteins that enable recruitment and activation 
of leukocytes at sites of vascular injury as well as platelet 
adhesion to the endothelium. The interaction between 
the three types of cells creates a mutual feedback loop of 
reciprocal activation and inhibition leading to modulation 
of the inflammatory process (23,24). 
Galectin-1, -3 and -8 are strong inducers of P-selectin 
expression (7,9,10). The major role of P-selectin on the platelet 
surface is the interaction with P-selectin glycoprotein ligand 
(PSGL-1), its counter-receptor on leukocytes, to form platelet-
leukocyte aggregates (25). In fact, activation of platelets 
by galectin-1 in the presence of polymorphonuclear 
leukocytes results in a significant formation of heterotypic 
cell aggregates (7,9). The interaction of platelets with 
leukocytes promotes activation of both cell types, which is 
a crucial condition for triggering inflammation, vascular 
remodelling and thrombosis. Platelet-leukocyte aggregates 
represent an established link between inflammation and 
thrombosis in acute syndromes including coronary diseases 
and related disorders (26). The expression of P-selectin 
on the platelet surface, the formation of leukocyte-
platelets aggregates and leukocyte activation are relevant 
events in deep vein thrombosis (DVT) (27). Given that 
galectins promote all these responses, binding of these 
lectins to platelets might represent potentially novel 
mechanism involved in DVT. Interestingly, galectin-3 
binding protein has been found to be up-regulated in 
proteomics analysis of MP during DVT (28). While 
galectin-8 has been linked to proinflammatory processes 
(29,30), both, anti and proinflammatory activities have 
been ascribed to galectin-1 (6). Whether antiinflammatory 
effects occur at low concentrations of galectin-1, while 
proinflammatory effects prevail at high concentrations, 
still remains to be established. The fact that galectin-1 
promotes platelet activation support the notion that 
under certain circumstances, galectin-1 could also act as a 
proinflammatory factor.
The interaction of P-selectin with PSGL-1 induces the 
up-regulation of tissue factor in the leukocyte membrane 
and the production of procoagulant MP. Besides, activation 
of platelets by galectin-1 (7) induces phosphatidylserine 
expressing MPs thus providing a catalytic surface for several 
enzyme complexes of the coagulation system. Together, 
these data indicate that either in a direct manner or through 
the activation of leukocytes, platelet-galectin interactions 
might contribute to activate the coagulation cascade thereby 
contributing to a prothrombotic state.
Similarly to P-selectin, vWF is stored in platelet α 
granules and in Weibel-Palade bodies of endothelial cells 
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from which is released during injury or inflammation. vWF 
is a large multimeric glycoprotein that allows platelet-
endothelium, platelet-subendothelium and platelet-
platelet interaction and is therefore important for platelet 
adhesion and thrombus formation, vWF is a biomarker 
for endothelial dysfunction and cardiovascular risk and 
high levels of vWF are found in both chronic and acute 
inflammation (31). The release of α granule stored vWF 
occurs after activation of platelets by galectin-1 (unpublished 
data) or -8 (9). Thus, P-selectin expression and vWF release 
mediated by galectins might play an important role in the 
pathogenesis of thrombus formation and the modulation of 
inflammatory responses.
Atherosclerosis is an inflammatory disorder and the 
interaction between activated endothelial cells and platelets 
has a major role in the initiation and progression of the 
atheroma plaque. We recently observed that platelets 
adhere to galectin-8-treated endothelial cells, strongly 
suggesting that galectin-8 might trigger an activation state 
on the endothelium in an inflammatory context (11). In 
this sense, we also found that galectin-8 induces a plethora 
of proinflammatory molecules in the endothelium that 
might not only trigger the local platelet adhesion/activation 
processes but also fuels a given pathological abnormality 
such as atherosclerosis. Although the expression of 
galectin-8 in human atherosclerotic lesions has not yet 
been explored, several groups demonstrated that galectins 
including galectin-1 participate in the initiation, progression 
and rupture of an atheroma plaque. Galectin-1, -3 and -8 
are not only expressed by the different cellular components 
of the atheroma lesions (32-34) but they also promote 
smooth muscle cell proliferation and transformation of 
macrophages into foam cells through the uptake of modified 
lipoproteins or advanced glycation end products (AGEs) 
(35,36). The expression of galectins in the inner of atheroma 
plaque may not only represent strong amplifiers of platelet 
activation but may also be key components of the extremely 
thrombogenic core exposed after plaque rupture, the main 
trigger for acute thrombus formation and cause of unstable 
angina, myocardial infarction, transient ischemic attack, and 
stroke. Evidence for a role of galectins in atherosclerosis 
has also emerged from whole-genome association studies 
for myocardial infarction in Asian populations (32) although 
these findings were not reproduced in studies of populations 
with other ancestries (37).
It has been extensively shown that depletion or 
functional inactivation of platelets through a variety of 
genetic and pharmacological manipulations markedly 
reduces tumor progression and metastasis. Platelets 
may influence the metastatic potential of tumor cells via 
several mechanisms: (I) through the release of a variety of 
inflammatory mediators which may influence tumor growth 
and stroma formation; (II) through the expression of 
P-selectin, platelets may contribute to the stable adhesion to 
endothelium and/or transmigration of tumor cells outside of 
the vasculature; (III) through the formation of heterotypic 
aggregates between mucins in circulating cancer and 
P-selectin in activated platelets which may protect tumor 
cells against immune attack (38). The formation of mixed-
cell aggregates between tumor cells expressing high levels of 
galectins and platelets might also represent a complementary 
molecular mechanism to mucins and P-selectin interaction 
by which platelets contribute to tumor progression and 
metastasis. Interestingly, and in contrast to mucin—P-selectin 
interactions, the interaction of tumor cells with platelets via 
galectins would not require the presence of activated platelets.
Control of angiogenesis by galectins involves 
the release of platelet-derived proangiogenic 
factors
Platelets are being recognized as major players in every step 
of vessel formation as they are a major storage of a broad 
array of growth factors, chemokines, cytokines, proteases 
and cell adhesion molecules (39). The pro-angiogenic 
substances contained within platelets include vascular 
endothelial growh factor (VEGF), basic fibroblast growth 
factor, platelet derived growth factor, epithelial growth 
factor, and stromal cell-derived factor-1α. Additionally, anti-
angiogenic molecules are secreted by platelets and these 
include thrombospondin-1, endostatin, platelet factor-4, 
angiostatin, tissue inhibitor of metalloproteinases-1 
and -4 and plasminogen activator inhibitor-1. It has 
been recently demonstrated that angiogenic factors 
are packed into morphologically distinct populations 
of α-granules in megakaryocytes and platelets (40,41) 
and can be differentially released based on selective 
engagement of platelet receptors, providing a mechanism 
by which platelets can locally and sequentially modulate 
angiogenesis (41). Although platelets contain both, pro and 
antiangiogenic molecules, there is a general consensus that 
platelets promote angiogenesis by stimulating chemotaxis, 
proliferation, and differentiation of endothelial cells and 
recruitment of progenitor cells to sites of vascular injury. 
The amplification of angiogenesis by platelets plays a 
positive and beneficial role in several processes, such as 
Schattner. Platelet activation by galectins
© Annals of Translational Medicine. All rights reserved. Ann Transl Med 2014;2(9):85www.atmjournal.org
Page 6 of 7
pregnancy and tissue healing, where new vessel development 
is required. However, in clinical conditions associated 
with abnormal or excessive angiogenesis including cancer, 
atherosclerosis, and arthritis, platelets might contribute to 
the detrimental progression of these diseases.
Different members of the galectin family can selectively 
regulate the release of angiogenic molecules by platelets. 
Whereas galectin-1, -3, and -8 trigger VEGF release, only 
galectin-8 induce endostatin secretion (10). The ability of all 
three galectins to trigger VEGF release, but only galectin-8 
being able to induce endostatin secretion is in agreement 
with the new paradigm of platelet granule secretion 
described above and point out that the differential release 
of VEGF or endostatin is not restricted to classical platelet 
agonists but can also be induced by non-canonical platelet 
activators such as galectins. Despite VEGF or endostatin 
secretion, platelet releasates generated by stimulation with 
each galectin stimulate angiogenic responses in vitro including 
endothelial cell proliferation and tubulogenesis. The platelet-
angiogenic activity is independent of VEGF and is associated 
to the concerted action of other pro-angiogenic molecules 
distinctly released by each galectin (10). Altogether, these 
data highlights that secretion of platelet-derived angiogenic 
molecules may represent an alternative mechanism by which 
galectins promote angiogenic responses and its selective 
blockade may lead to the development of therapeutic 
strategies for angiogenesis-related diseases.
Perspectives
Over the last decade we have witnessed impressive advances 
regarding the biology of galectins and their role in cell 
homeostasis, in particular as regulators of the immune 
response. The information currently available indicates that 
galectins are expressed and secreted by several cell types 
in normal and pathological conditions. The emergence of 
galectins as soluble mediators capable of triggering platelet 
activation opens a new field of research that will provide 
further insights into the mechanisms linking inflammatory 
responses to thrombus formation and could expand our view 
of the role of platelets much beyond hemostasis to their 
pathophysiologic role during inflammation and cancer. As 
galectins are up-regulated in endothelial cells and tumors, 
and galectin stimulation results in platelet aggregation 
and secretion of soluble pro-angiogenic factors, selective 
targeting of these pathways may contribute to design novel 
therapeutic approaches to promote tissue regeneration and 
attenuate atherosclerosis, ischemic ulcers, diabetes or cancer.
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